Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00326664 · ClinicalTrials.gov registry record · Phase 1
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 55
- Enrollment target
NCT00326664: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00326664 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 55 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00326664, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 55 participants
- Enrollment target
Study Summary
This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Interventions
- DRUG Cediranib Maleate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 55 participants |
| Start Date | 2006-03 |
| Est. Completion | 2015-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00326664
The ClinicalTrials.gov registry entry for NCT00326664 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 55 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Cediranib Maleate is the first listed.
NCT00326664 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00326664 about?
NCT00326664 is a clinical study titled "AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors". This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor...
What is the current status of trial NCT00326664?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 55 participants. The study started on 2006-03. Estimated completion is 2015-07.
What interventions are being tested in trial NCT00326664?
The interventions under investigation include: Cediranib Maleate (DRUG).
Who is sponsoring clinical trial NCT00326664?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.